Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    JACC: CardioOncology Pulse - SGLT2 Inhibitors and Withdrawal of Neurohormonal Therapy in Cancer Therapy-Related Cardiotoxicity: What Is the Evidence?

    JACC: CardioOncology Pulse - SGLT2 Inhibitors and Withdrawal of Neurohormonal Therapy in Cancer Therapy-Related Cardiotoxicity: What Is the Evidence?

    FromJACC Specialty Journals

    Start listeningView podcast show

    JACC: CardioOncology Pulse - SGLT2 Inhibitors and Withdrawal of Neurohormonal Therapy in Cancer Therapy-Related Cardiotoxicity: What Is the Evidence?

    FromJACC Specialty Journals

    ratings:
    Length:
    24 minutes
    Released:
    May 29, 2024
    Format:
    Podcast episode

    Description

    JACC: CardioOncology Editor-in-chief, Bonnie Ky, MD, MSCE, FACC and Dinesh Thavendiranathan, MD, MSc, Husam Abdel-Qadir, MD, PhD and Christopher Yu, MBBS discuss recent studies of SGLT2 inhibitors and withdrawal of neurhormonal therapy for cancer therapy-related cardiotoxicity.
    Released:
    May 29, 2024
    Format:
    Podcast episode

    Titles in the series (100)

    In this podcast series, editors-in-chief from the JACC family of specialty journals provide highlights and summarize key findings for select issues. Published by the American College of Cardiology, the JACC Journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the art papers, and review articles. They are top ranked for impact factor and their manuscripts are among the most covered by media outlets, most talked about on social media, and most read online.